The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19

Q Hu, Y Xiong, GH Zhu, YN Zhang, YW Zhang… - MedComm, 2022 - Wiley Online Library
The main proteases (Mpro), also termed 3‐chymotrypsin‐like proteases (3CLpro), are a
class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has …

Targeting SARS-CoV-2 main protease for treatment of COVID-19: covalent inhibitors structure–activity relationship insights and evolution perspectives

G La Monica, A Bono, A Lauria… - Journal of medicinal …, 2022 - ACS Publications
The viral main protease is one of the most attractive targets among all key enzymes involved
in the SARS-CoV-2 life cycle. Covalent inhibition of the cysteine145 of SARS-CoV-2 MPRO …

Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2

N Drayman, JK DeMarco, KA Jones, SA Azizi… - Science, 2021 - science.org
There is an urgent need for antiviral agents that treat severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection. We screened a library of 1900 clinically safe drugs …

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

L Riva, S Yuan, X Yin, L Martin-Sancho, N Matsunaga… - Nature, 2020 - nature.com
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019
has triggered an ongoing global pandemic of the severe pneumonia-like disease …

Rapid identification of potential inhibitors of SARS‐CoV‐2 main protease by deep docking of 1.3 billion compounds

AT Ton, F Gentile, M Hsing, F Ban… - Molecular …, 2020 - Wiley Online Library
Abstract The recently emerged 2019 Novel Coronavirus (SARS‐CoV‐2) and associated
COVID‐19 disease cause serious or even fatal respiratory tract infection and yet no …

Recent discovery and development of inhibitors targeting coronaviruses

T Pillaiyar, S Meenakshisundaram, M Manickam - Drug discovery today, 2020 - Elsevier
Human coronaviruses (CoVs) are enveloped viruses with a positive-sense single-stranded
RNA genome. Currently, six human CoVs have been reported including human coronavirus …

Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review

X Li, Y Song - European Journal of Medicinal Chemistry, 2023 - Elsevier
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) identified in 2003
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …

Drug development and medicinal chemistry efforts toward SARS‐coronavirus and Covid‐19 therapeutics

AK Ghosh, M Brindisi, D Shahabi… - …, 2020 - Wiley Online Library
The COVID‐19 pandemic caused by SARS‐CoV‐2 infection is spreading at an alarming
rate and has created an unprecedented health emergency around the globe. There is no …

A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication

S Hattori, N Higashi-Kuwata, H Hayashi, SR Allu… - Nature …, 2021 - nature.com
Except remdesivir, no specific antivirals for SARS-CoV-2 infection are currently available.
Here, we characterize two small-molecule-compounds, named GRL-1720 and 5h …

[HTML][HTML] Artificial intelligence approach fighting COVID-19 with repurposing drugs

YY Ke, TT Peng, TK Yeh, WZ Huang, SE Chang… - Biomedical journal, 2020 - Elsevier
Background The ongoing COVID-19 pandemic has caused more than 193,825 deaths
during the past few months. A quick-to-be-identified cure for the disease will be a therapeutic …